Home HOME Neoplasma 2021 Neoplasma Vol.68, No.4, p.683–691, 2021

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.68, No.4, p.683–691, 2021

Title: DNase1L3 suppresses hepatocellular carcinoma growth via inhibiting complement autocrine effect
Author: Qing-Yun Chen, Lei Li, Da-Qin Suo

Abstract: Hepatocellular carcinoma (HCC) is one of the most aggressive types of cancer and currently lacks effective treatment strategies. The present study revealed that deoxyribonuclease 1 like 3 (DNase1L3) expression levels were significantly downregulated in numerous types of gastrointestinal cancer, and especially in HCC. Tissue microarrays were further used to illustrate that DNase1L3 expression levels were frequently downregulated in HCC tissues compared with normal liver tissues.
In addition, DNase1L3 expression levels were identified to be significantly associated with tumor size (P = 0.0028), tumor thrombus formation (P of biological processes discovered that DNase1L3 was significantly associated with complement activation. Further studies demonstrated that the ectopic expression of DNase1L3 suppressed cell growth and inhibited the PI3K/AKT signaling pathway activation following C3a receptor agonist treatment. In conclusion, the findings of the present study suggested, for the first time, that DNase1L3 may serve as a biomarker for the prognosis of patients with HCC, and may suppress HCC growth via inhibiting the PI3K/AKT signaling pathway.

Keywords: HCC; DNase1L3; complement; PI3K/AKT
Published online: 23-Feb-2021
Year: 2021, Volume: 68, Issue: 4 Page From: 683, Page To: 691

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.